Lingshuang Sheng

433 total citations
12 papers, 189 citations indexed

About

Lingshuang Sheng is a scholar working on Oncology, Immunology and Hematology. According to data from OpenAlex, Lingshuang Sheng has authored 12 papers receiving a total of 189 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Immunology and 3 papers in Hematology. Recurrent topics in Lingshuang Sheng's work include CAR-T cell therapy research (7 papers), Immune Cell Function and Interaction (5 papers) and Biosimilars and Bioanalytical Methods (2 papers). Lingshuang Sheng is often cited by papers focused on CAR-T cell therapy research (7 papers), Immune Cell Function and Interaction (5 papers) and Biosimilars and Bioanalytical Methods (2 papers). Lingshuang Sheng collaborates with scholars based in China, United Kingdom and France. Lingshuang Sheng's co-authors include Weili Zhao, Zi‐Xun Yan, Li Wang, Liang Huang, Li Li, Qing Li, Pengpeng Xu, Di Fu, Na Wang and Wenyue Cao and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

Lingshuang Sheng

11 papers receiving 186 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lingshuang Sheng China 7 123 51 45 39 29 12 189
Forat Lutfi United States 10 194 1.6× 54 1.1× 24 0.5× 39 1.0× 44 1.5× 49 257
Xiaolu Long China 9 133 1.1× 34 0.7× 22 0.5× 75 1.9× 31 1.1× 22 233
Marta Español‐Rego Spain 9 52 0.4× 52 1.0× 19 0.4× 43 1.1× 16 0.6× 15 149
Kissy Guevara‐Hoyer Spain 9 67 0.5× 127 2.5× 37 0.8× 31 0.8× 21 0.7× 28 212
Uri Greenbaum Israel 9 117 1.0× 55 1.1× 18 0.4× 37 0.9× 23 0.8× 26 232
Marta García‐Recio Spain 6 245 2.0× 39 0.8× 23 0.5× 46 1.2× 71 2.4× 12 294
Anant Vatsayan United States 7 78 0.6× 35 0.7× 16 0.4× 19 0.5× 24 0.8× 21 146
Stefano Di Cecca Italy 10 61 0.5× 109 2.1× 74 1.6× 65 1.7× 52 1.8× 13 226
Núria Martínez‐Cibrián Spain 9 189 1.5× 63 1.2× 16 0.4× 44 1.1× 46 1.6× 23 286
Aishat Olaide Afuye United States 4 250 2.0× 39 0.8× 23 0.5× 46 1.2× 79 2.7× 4 275

Countries citing papers authored by Lingshuang Sheng

Since Specialization
Citations

This map shows the geographic impact of Lingshuang Sheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingshuang Sheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingshuang Sheng more than expected).

Fields of papers citing papers by Lingshuang Sheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lingshuang Sheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingshuang Sheng. The network helps show where Lingshuang Sheng may publish in the future.

Co-authorship network of co-authors of Lingshuang Sheng

This figure shows the co-authorship network connecting the top 25 collaborators of Lingshuang Sheng. A scholar is included among the top collaborators of Lingshuang Sheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lingshuang Sheng. Lingshuang Sheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Cao, Weiguo, Wang Li, Lingshuang Sheng, et al.. (2025). Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study. Clinical and Translational Medicine. 15(4). e70310–e70310. 1 indexed citations
2.
3.
Yan, Zi‐Xun, Lingshuang Sheng, Li Wang, et al.. (2024). A phase 1 study of LY007, a novel anti-CD20 CAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 7027–7027. 2 indexed citations
4.
Sheng, Lingshuang, Yilun Zhang, Qi Song, et al.. (2023). Concurrent remission of lymphoma and Sjögren’s disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report. Frontiers in Immunology. 14. 1298815–1298815. 26 indexed citations
5.
Sheng, Lingshuang, Di Fu, Yiwen Cao, et al.. (2022). Integrated Genomic and Transcriptomic Analyses of Diffuse Large B-Cell Lymphoma With Multiple Abnormal Immunologic Markers. Frontiers in Oncology. 12. 790720–790720. 6 indexed citations
6.
Li, Li, Qing Li, Zi‐Xun Yan, et al.. (2022). Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells. Scientific Reports. 12(1). 12506–12506. 38 indexed citations
7.
8.
Yang, Yang, et al.. (2021). Chronic active Epstein-Barr virus infection progresses to aggressive NK cell leukemia with a poor prognosis.. American Journal of Translational Research. 13(10). 12006–12015. 2 indexed citations
9.
Li, Wei‐Ming, Guolin Yuan, Zhuangzhi Yang, et al.. (2020). COVID-19 in persons with chronic myeloid leukaemia. Leukemia. 34(7). 1799–1804. 56 indexed citations
10.
Sheng, Lingshuang, Xiong Wang, Ning Tang, et al.. (2020). Clinical characteristics of moderate and severe cases with COVID-19 in Wuhan, China: a retrospective study. Clinical and Experimental Medicine. 21(1). 35–39. 12 indexed citations
11.
Sheng, Lingshuang, et al.. (2019). Novel mutations of STXBP2 and LYST associated with adult haemophagocytic lymphohistiocytosis with Epstein-Barr virus infection: a case report. BMC Medical Genetics. 20(1). 34–34. 6 indexed citations
12.
Xu, Hao, Na Wang, Wenyue Cao, et al.. (2018). Influence of various medium environment to in vitro human T cell culture. In Vitro Cellular & Developmental Biology - Animal. 54(8). 559–566. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Forat Lutfi Breakdown of academic impact, for papers by Xiaolu Long Breakdown of academic impact, for papers by Marta Español‐Rego Breakdown of academic impact, for papers by Kissy Guevara‐Hoyer Breakdown of academic impact, for papers by Uri Greenbaum Breakdown of academic impact, for papers by Marta García‐Recio Breakdown of academic impact, for papers by Anant Vatsayan Breakdown of academic impact, for papers by Stefano Di Cecca Breakdown of academic impact, for papers by Núria Martínez‐Cibrián Breakdown of academic impact, for papers by Aishat Olaide Afuye
Rankless by CCL
2026